Advanced Medical Optics Names Dr. Simon Kilvington Director of Microbiology

SANTA ANA, Calif.--()--Advanced Medical Optics, Inc. (AMO) (NYSE:EYE), the global leader in advanced refractive technologies for eye care professionals and patients, has named Simon Kilvington, Ph.D., director of microbiology. Dr. Kilvington will be responsible for scientific and managerial leadership of AMOs microbiology activities in support of the discovery and development of new products for contact lens and corneal care.

As an internationally recognized leader in microbiological research on contact lenses, lens care and the cornea, Dr. Kilvingtons appointment will significantly strengthen AMOs research efforts into the development of novel technologies, particularly in the field of contact lens disinfection, said AMO Executive Vice President, Research and Development Leonard Borrmann. We also look forward to his continued collaboration with external thought leaders and academic research centers.

Prior to joining AMO, Dr. Kilvington was senior lecturer at the Department of Infection, Immunity and Inflammation at the University of Leicester in the United Kingdom (U.K.). He is an international authority on pathogenic free-living amoebae and has expertise on bacteria, fungi and viruses, particularly in the field of ocular infection. He has published extensively in the field of contact lens disinfection, the epidemiology of infection and the development of assay methods to assess the efficacy of contact lens disinfectant and therapeutic agents.

Dr. Kilvington has broad experience as a consultant and researcher with the pharmaceutical, contact lens and water treatment industries. At the University of Leicester, he taught medical microbiology to undergraduate and postgraduate students and is regularly invited to present research findings at national and international scientific conferences.

Dr. Kilvington received his Ph.D. from the University of Bath, U.K.

About Advanced Medical Optics (AMO)

AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract line include monofocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as Tecnis®, Clariflex® and Sensar® IOLs; Sovereign®, Sovereign® Compact and WhiteStar Signature phacoemulsification systems with WhiteStar® technology; Healon® viscoelastics and the Baerveldt® glaucoma shunt. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards, and refractive implants. AMO brands in the refractive business include iDesign, iFS, Star S4 IR®, WaveScan Wavefront®, Advanced CustomVue, IntraLase®, IntraLasik® and ReZoom®, Tecnis® Multifocal and Verisyse® IOLs. Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears. Among the eye care product brands the company possesses are COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®, Ultrazyme®, Total Care and blink® branded products. AMO is based in Santa Ana, California, and employs approximately 4,000 worldwide. The company has operations in 30 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements about AMO, including the statement by Dr. Borrmann and statements relating to development of novel technologies in contact lens care. All forward-looking statements in this press release represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors, including, but not limited to, unexpected delays or costs associated with the research and development of testing standards and new formulas for contact lens care products, continued acceptance of our current products, and unexpected changes in competitive, regulatory and market conditions. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2007 Form 10-K filed in March 2008. Copies of press releases and additional information about AMO are available at www.amo-inc.com.

Contacts

Advanced Medical Optics, Inc.
Investors:
Sheree Aronson, Corporate Vice President,
Investor Relations and Corporate Communications
714-247-8290
sheree.aronson@amo-inc.com
Media:
Steve Chesterman, Manager, Corporate Communications
714-247-8711
steve.chesterman@amo-inc.com

Contacts

Advanced Medical Optics, Inc.
Investors:
Sheree Aronson, Corporate Vice President,
Investor Relations and Corporate Communications
714-247-8290
sheree.aronson@amo-inc.com
Media:
Steve Chesterman, Manager, Corporate Communications
714-247-8711
steve.chesterman@amo-inc.com